Sign inJoin waitlistJoin the waitlist

Lajos Pusztai

Co-Leader, Genetics, Genomics and Epigenetics, Yale Cancer Center · Yale-New Haven Hospital

Credentials: · · · · · ·

History

Genetics · Yale-New Haven Hospital
Present
Genetics · Yale Cancer Center
Present
Yale-New Haven Hospital · Yale University
Present

University of Texas MD Anderson Cancer Center
1996–1999
University of Rochester St. Mary's Hospital
1994–1996
University of Rochester St. Mary's Hospital
1993–1994
Nuffield Orthopedic Center- Oxford University UK
1990–1993
University of Oxford
SEMMELWEIS ORVOSTUDOMANYI EGYETEM (PETER PAZMANY UNIV), BUDAPEST
1983–1987
University of Oxford
1979–1983

Research

Pembrolizumab for Early Triple-Negative Breast Cancer
New England Journal of Medicine · 2020 · 2,567 citations
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Journal of Clinical Oncology · 2008 · Last of 13 authors · 2,356 citations
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Nature Biotechnology · 2013 · 1,863 citations

Gabriel Hortobagyi
153 papers
William Symmans
144 papers
Vicente Valero
49 papers
FE
Francisco Esteva
35 papers
Jeffrey Ross
33 papers
DR
David Rimm
32 papers
Kathy Albain
30 papers
Laura Esserman
29 papers
Aman Buzdar
26 papers
Henry Kuerer
25 papers
Angela DeMichele
24 papers
Massimo Cristofanilli
24 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $247.7K · Yale University
1997–2029
Serum Biomarkers to Predict Immune Related Adverse Events and Benefit from Single Agent Pembrolizumab Therapy in Early Stage Triple Negative Breast Cancer
National Cancer Institute · R01
PI · $1.9M · Arizona State University-Tempe Campus
2023–2028
Immune Biological Differences Between Triple Negative Breast Cancer in African American and Non-African American Women and Potential Immunotherapy Opportunities to Improve Treatment Outcome
National Cancer Institute · R01
Contact PI · $2M · Yale University
2017–2022
Preoperative Chemotherapy for Breast Cancer
National Cancer Institute · R01
Contact PI · $569.7K · University of Tx Md Anderson Can Ctr
2005–2008

Clinical trials

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Principal investigator · Active not recruiting · Phase 2
Criterium, Inc.
2021–2028
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2017–2027
A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter
Principal investigator · Withdrawn · Phase 1, Phase 2
Yale University
2016–2018
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
Principal investigator · Completed · Phase 1, Phase 2
Yale University
2015–2021